Question 1

Which works better for weight loss, Foundayo or Rybelsus?

Accepted Answer

Foundayo recorded −11.1% to −12.4% at 72 wk (ATTAIN-1, 17.2 mg); Rybelsus recorded −4.4 kg (~−4%) at 26 wk (PIONEER 1, 14 mg). ⚠ These come from separate trials with different protocols and populations, so the gap between two numbers from two studies is weaker evidence than it looks. No head-to-head trial of this pair is on record here.

Question 2

Are Foundayo and Rybelsus the same drug?

Accepted Answer

No. Foundayo is orforglipron and Rybelsus is semaglutide (oral) — different molecules, and they work differently: Non-peptide small-molecule GLP-1 receptor agonist against Peptide GLP-1 agonist (semaglutide + SNAC absorption enhancer). Results with one do not predict results with the other.

Question 3

Is Foundayo or Rybelsus cheaper?

Accepted Answer

On the manufacturers' own cash pricing: Foundayo at Launched April 2026; direct-pay pricing was still settling, Rybelsus at About $1,029/mo retail. ⚠ That is the list-price comparison, and it is not what most people pay. What you actually pay depends on whether your plan covers it, which formulary tier it sits in, and whether you have met your deductible — and for many people the honest comparison is between an insured copay and a cash-pay compounded alternative rather than between these two figures.

Question 4

What does a compounded version of each actually cost?

Accepted Answer

Across the 556 sellers in this register, the cheapest standing monthly cash prices we hold are orforglipron from $149 a month and semaglutide (oral) from $79 a month. ⛔ A compounded preparation is not the approved product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed once the shortages closed. The price gap is real and so is the difference in oversight.

Question 5

Can I switch from Foundayo to Rybelsus?

Accepted Answer

Yes, with a prescriber. Expect to re-titrate from the bottom of the new drug's ladder rather than starting where you left off: these are different molecules and tolerance to one does not transfer to the other. Both the old drug's washout and the new drug's schedule apply.

Question 6

Which one should I ask for?

Accepted Answer

That is a prescriber's call, and anyone answering it from a table is guessing. What a page like this can do is tell you what the trials measured, what the manufacturers charge, and where the evidence is still missing, so the conversation starts from the record rather than from an advertisement.

Field	Foundayo	Rybelsus
Mechanism	Non-peptide small-molecule GLP-1 receptor agonist	Peptide GLP-1 agonist (semaglutide + SNAC absorption enhancer)
Approved doses	0.8 → 2.5 → 5.5 → 9 → 14.5 → 17.2 mg once daily	3 mg → 7 mg → 14 mg once daily
Weight loss (max dose, obesity)	−11.1% to −12.4% at 72 wk (ATTAIN-1, 17.2 mg)	−4.4 kg (~−4%) at 26 wk (PIONEER 1, 14 mg)
A1C reduction (T2D)	−1.3% to −1.6% / 40 wk (ACHIEVE-1, 17.2 mg)	−0.9% to −1.4% / 26 wk (PIONEER 1, 14 mg)
FDA-approved indication	Type 2 diabetes (2025); chronic weight management (2025)	Type 2 diabetes only (2019)
Once-daily food restriction	None — take with or without food, any time of day	Empty stomach + max 4 oz plain water + 30-min fast after
The complaint people report most	Nausea, roughly 20-30% and rising with dose	Nausea, about 16% at the 14 mg dose
What it costs if you pay cash	Launched April 2026; direct-pay pricing was still settling	About $1,029/mo retail

Foundayo vs Rybelsus: The Two Oral GLP-1s

The verdict

Side-by-side comparison

What each one costs in the compounded market

Frequently asked questions